You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 18, 2025

CLINICAL TRIALS PROFILE FOR OXYCODONE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for Oxycodone Hydrochloride

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
OTC NCT00245375 ↗ A Trial Comparing Combination Therapy of Acetaminophen Plus Ibuprofen Versus Tylenol #3 for the Treatment of Pain After Outpatient Surgery Completed McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. N/A 2005-01-01 Increasingly in general surgery, the investigators are conducting outpatient day surgery. Ambulatory surgery currently comprises 60 to 70% of surgeries performed in North America. These patients all require some form of analgesia which can be taken at home in the first few days after the surgery. The current standard at the investigators' centre and many others in the maritime provinces is to provide a prescription for oral acetaminophen plus codeine or oxycodone (Tylenol #3®, Percocet ®). Some patients may receive more potent opioids such as oral hydromorphone (Dilaudid®). Unfortunately, the most commonly prescribed medication (Tylenol #3®) is often poorly tolerated by patients, has several undesirable side effects, and may not provide effective pain relief. In the investigators' experience, non-steroidal anti-inflammatory drugs (NSAIDs) are uncommonly a routine addition to the home analgesic regimen. Tylenol #3®, in the investigators' experience and opinion, is a poor post surgical pain medication. They hope to show that a combination of ibuprofen and acetaminophen is better for pain relief after these procedures. The combination of acetaminophen and ibuprofen would be a safe, cheap, and readily available regimen. Unfortunately, as the prescribing practices of surgeons are old habits, it will require a very convincing argument to get them to change their practices. A randomized controlled trial comparing these two regimens, the investigators hope, would be a powerful enough argument. The hypothesis of this study, therefore, is that the pain control provided by a combination of acetaminophen plus ibuprofen (650 mg/400 mg four times per day) will be superior to Tylenol #3® (600 mg acetaminophen/60 mg codeine/15 mg caffeine four times per day). This study will attempt to enroll 150 patients in total. Eligible patients will be identified by their attending surgeon and contacted by study personnel. Patients who enroll in the study will undergo their surgery in the usual manner. After the surgery, in the recovery room, once they are ready to go home, they will be randomized to receive combination A or B and be given a week's worth of pain medication. They will then go home and take this medication as directed. They will record their pain intensity and pain relief once per day using a diary provided in the study package. One week after their surgery, they will return to the hospital clinic and be seen by the study nurse. They will hand over the diary and any unused medication. They will also be asked several questions regarding their overall satisfaction, incidence of side effects, and how long until they were pain free. The risks of participating in this study are minimal from the risks inherent to the procedures and medications the patients would receive within the standard of care. Ibuprofen is a commonly used NSAID which is widely available over the counter and has an established safety profile. The most common adverse effects of ibuprofen and other NSAIDs are gastrointestinal bleeding and ulceration. Other less common adverse effects include nephrotoxicity, hypersensitivity reactions, hepatic dysfunction (longterm use), and cognitive dysfunction. The investigators' patients will be selected to exclude those most at risk for these complications (see exclusion criteria). Acetaminophen has few side effects, with no adverse effects on platelet function and no evidence of gastric irritation.
OTC NCT00245375 ↗ A Trial Comparing Combination Therapy of Acetaminophen Plus Ibuprofen Versus Tylenol #3 for the Treatment of Pain After Outpatient Surgery Completed Nova Scotia Health Authority N/A 2005-01-01 Increasingly in general surgery, the investigators are conducting outpatient day surgery. Ambulatory surgery currently comprises 60 to 70% of surgeries performed in North America. These patients all require some form of analgesia which can be taken at home in the first few days after the surgery. The current standard at the investigators' centre and many others in the maritime provinces is to provide a prescription for oral acetaminophen plus codeine or oxycodone (Tylenol #3®, Percocet ®). Some patients may receive more potent opioids such as oral hydromorphone (Dilaudid®). Unfortunately, the most commonly prescribed medication (Tylenol #3®) is often poorly tolerated by patients, has several undesirable side effects, and may not provide effective pain relief. In the investigators' experience, non-steroidal anti-inflammatory drugs (NSAIDs) are uncommonly a routine addition to the home analgesic regimen. Tylenol #3®, in the investigators' experience and opinion, is a poor post surgical pain medication. They hope to show that a combination of ibuprofen and acetaminophen is better for pain relief after these procedures. The combination of acetaminophen and ibuprofen would be a safe, cheap, and readily available regimen. Unfortunately, as the prescribing practices of surgeons are old habits, it will require a very convincing argument to get them to change their practices. A randomized controlled trial comparing these two regimens, the investigators hope, would be a powerful enough argument. The hypothesis of this study, therefore, is that the pain control provided by a combination of acetaminophen plus ibuprofen (650 mg/400 mg four times per day) will be superior to Tylenol #3® (600 mg acetaminophen/60 mg codeine/15 mg caffeine four times per day). This study will attempt to enroll 150 patients in total. Eligible patients will be identified by their attending surgeon and contacted by study personnel. Patients who enroll in the study will undergo their surgery in the usual manner. After the surgery, in the recovery room, once they are ready to go home, they will be randomized to receive combination A or B and be given a week's worth of pain medication. They will then go home and take this medication as directed. They will record their pain intensity and pain relief once per day using a diary provided in the study package. One week after their surgery, they will return to the hospital clinic and be seen by the study nurse. They will hand over the diary and any unused medication. They will also be asked several questions regarding their overall satisfaction, incidence of side effects, and how long until they were pain free. The risks of participating in this study are minimal from the risks inherent to the procedures and medications the patients would receive within the standard of care. Ibuprofen is a commonly used NSAID which is widely available over the counter and has an established safety profile. The most common adverse effects of ibuprofen and other NSAIDs are gastrointestinal bleeding and ulceration. Other less common adverse effects include nephrotoxicity, hypersensitivity reactions, hepatic dysfunction (longterm use), and cognitive dysfunction. The investigators' patients will be selected to exclude those most at risk for these complications (see exclusion criteria). Acetaminophen has few side effects, with no adverse effects on platelet function and no evidence of gastric irritation.
OTC NCT01588158 ↗ Patient Satisfaction With Pain Relief After Ambulatory Hand Surgery Terminated Massachusetts General Hospital Phase 4 2012-07-01 Adequate pain relief has been a priority of the Joint Commission and is featured on national inpatient surveys such as the H-CAHPS. When considering methods for improving satisfaction with pain relief in the United States, a great deal of emphasis has been placed on opioid pain medications. Some of this emphasis on opioid pain medication is driven by the pharmaceutical industry and by advocacy groups with ties to the pharmaceutical industry. There is evidence that the "pain is the fifth vital sign" campaign of the Joint Commission led to an increased incidence of prescription of opioids, but there is less evidence of improved satisfaction with pain relief. There is some evidence of an increase in opioid-related adverse events. As the sales of opioids have tripled from 1999-2008, so has the number of deaths caused by opioid overdose; 14,800 in 2008. The number of visits to the Emergency Department for opioid overdose doubled between 2004 and 2008. Patients in other countries take far less opioid pain medication and are equally satisfied with pain relief. For instance, Lindenhovius et al. found in a retrospective study that Dutch patients take a weak (Tramadol) or no opioid pain medication after ankle fracture surgery and have comparable or better satisfaction with pain relief than American patients, most of whom take oxycodone. That study was repeated prospectively (unpublished) and confirmed that Dutch patients do not feel their pain is undertreated. A study of morphine use after a femur fracture demonstrated that American patients used far more than Vietnamese patients (30 mg/kg versus 0.9 mg/kg), but were more dissatisfied with their pain relief. These sociological differences are striking and suggest strongly that personal factors may be the most important determinant of satisfaction with pain relief. It is our impression that most American hand surgeons give patients a prescription for an opioid pain medication after carpal tunnel release, and that is certainly true in our practice. This seems to be based primarily on the outliers, and intended to avoid confrontation with patients that desire opioids; however, most patients take little or no narcotic pain medication, and many who do use the opioids complain of the side effects-nausea and pruritis in particular. It is therefore not clear whether routine opioids is the optimal pain management strategy after carpal tunnel release. In the study of Stahl et al. from Israel, patients were prescribed acetaminophen rather than opioids after carpal tunnel release and only 20 of 50 patients used acetaminophen; 30 patients did not use acetaminophen or other pain medication at all after the operation. Our aim is to determine if there is a difference in satisfaction with pain relief between patients advised to take opioids compared to patients advised to use over the counter acetaminophen after carpal tunnel release under local anesthesia. A secondary aim is to determine if personal factors account for more of the variability in satisfaction with pain relief than opioid strategy.
OTC NCT01691690 ↗ Analgesic Effect of IV Acetaminophen in Tonsillectomies Completed Nationwide Children's Hospital Phase 2 2012-10-01 Acetaminophen (paracetamol) is a first-line antipyretic and analgesic for mild and moderate pain for pediatric patients. Its common use (particularly in oral form) is underscored by its wide therapeutic window, safety profile, over the counter accessibility, lack of adverse systemic effects (as compared with NSAIDS and opioids) when given in appropriate doses. Although the exact anti-nociceptive mechanisms of acetaminophen continue to be elucidated, these mechanisms appear to be multi-factorial and include central inhibition of the cyclo-oxygenase (COX) enzyme leading to decreased production of prostaglandins from arachidonic acid, interference with serotonergic descending pain pathways, indirect activation of cannabinoid 1 (CB1) receptors and inhibition of nitric oxide pathways through N-methyl-D-aspartate (NMDA) or substance P. Of the above mechanisms, the most commonly known is that of central inhibition of COX enzymes by which the decreased production of prostaglandins diminish the release of excitatory transmitters of substance P and glutamate which are both involved in nociceptive transmission (Anderson, 2008; Smith, 2011). To date, several studies have shown acetaminophen's opioid sparing effect in the pediatric population when given by the rectal or intravenous routes (Korpela et al, 1999; Dashti et al, 2009; Hong et al, 2010).
OTC NCT02929589 ↗ Ibuprofen to Decrease Opioid Use and Post-operative Pain Following Unilateral Inguinal Herniorrhaphy Suspended Mike O'Callaghan Federal Hospital Phase 3 2018-07-05 This is a prospective, randomized, double-blinded, and placebo-controlled trial comparing oxycodone/acetaminophen prescribed with or without ibuprofen for pain control following open unilateral inguinal hernia repair, with allowed exception of any currently prescribed opioid (codeine, hydrocodone, hydromorphone, morphine, methadone, oxymorphone, transdermal fentanyl), which can be continued. The patients will not be allowed to continue any over-the-counter pain medications, such as ibuprofen, naproxen, or acetaminophen containing medications, that were not prescribed by the investigators during this study. Patients not receiving Ibuprofen will be given a placebo pill composed of corn starch. The placebo pill will be formulated into the same shape, size and color as the ibuprofen capsule. Neither the investigators nor the research subjects will know if the subject is receiving a placebo versus Ibuprofen. The subjects will complete pain level and medication diaries, and will be followed for 2 months after their surgery. The research aims to discover the appropriate amount of opioid medication to prescribe to patients undergoing an elective open inguinal hernia repair, and reduce the total opioid dose needed by utilizing ibuprofen in combination. The investigators expect that the subjects who take ibuprofen will use less oxycodone/acetaminophen, and have comparable or lower mean pain levels. This could contribute to reducing the surplus opioids prescribed by physicians after surgery, which can lead to opioid use disorders. This particular procedure is common in men, and the findings have the potential to decrease the symptoms and pain of Active Duty members and DoD beneficiaries who undergo an inguinal hernia repair, and are at risk for prescription drug abuse or dependence.
OTC NCT02929589 ↗ Ibuprofen to Decrease Opioid Use and Post-operative Pain Following Unilateral Inguinal Herniorrhaphy Suspended Mike O'Callaghan Military Hospital Phase 3 2018-07-05 This is a prospective, randomized, double-blinded, and placebo-controlled trial comparing oxycodone/acetaminophen prescribed with or without ibuprofen for pain control following open unilateral inguinal hernia repair, with allowed exception of any currently prescribed opioid (codeine, hydrocodone, hydromorphone, morphine, methadone, oxymorphone, transdermal fentanyl), which can be continued. The patients will not be allowed to continue any over-the-counter pain medications, such as ibuprofen, naproxen, or acetaminophen containing medications, that were not prescribed by the investigators during this study. Patients not receiving Ibuprofen will be given a placebo pill composed of corn starch. The placebo pill will be formulated into the same shape, size and color as the ibuprofen capsule. Neither the investigators nor the research subjects will know if the subject is receiving a placebo versus Ibuprofen. The subjects will complete pain level and medication diaries, and will be followed for 2 months after their surgery. The research aims to discover the appropriate amount of opioid medication to prescribe to patients undergoing an elective open inguinal hernia repair, and reduce the total opioid dose needed by utilizing ibuprofen in combination. The investigators expect that the subjects who take ibuprofen will use less oxycodone/acetaminophen, and have comparable or lower mean pain levels. This could contribute to reducing the surplus opioids prescribed by physicians after surgery, which can lead to opioid use disorders. This particular procedure is common in men, and the findings have the potential to decrease the symptoms and pain of Active Duty members and DoD beneficiaries who undergo an inguinal hernia repair, and are at risk for prescription drug abuse or dependence.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Oxycodone Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000273 ↗ A Laboratory Model for Heroin Abuse Medications - 8 Completed National Institute on Drug Abuse (NIDA) Phase 2 1995-08-01 The purpose of this study is to evaluate the effects of treatment medications (methadone, buprenorphine, LAAM, naltrexone, naltrexone microcapsules, and methoclocinnamox) on I.V. and smoked heroin self-administration."
NCT00000273 ↗ A Laboratory Model for Heroin Abuse Medications - 8 Completed New York State Psychiatric Institute Phase 2 1995-08-01 The purpose of this study is to evaluate the effects of treatment medications (methadone, buprenorphine, LAAM, naltrexone, naltrexone microcapsules, and methoclocinnamox) on I.V. and smoked heroin self-administration."
NCT00027014 ↗ Herb-Opioid Interactions Completed National Center for Complementary and Integrative Health (NCCIH) Phase 4 2001-09-01 This is a series of studies in healthy volunteers to assess the potential for adverse interactions between St. John's wort (SJW) extract and two narcotic (opioid) pain medications: oxycodone and fentanyl. In the case of oxycodone, we are interested in whether SJW treatment promotes the metabolism of oxycodone, such that it lowers the effectiveness of standard doses of oxycodone in treating pain problems. For the fentanyl study, we will investigate whether SJW treatment will interfere with the delivery of fentanyl to the brain and diminish it's effectiveness to relieve pain. There is evidence to suggest that SJW treatment may increase the activity of a transporter protein, named P-glycoprotein (Pgp), in the blood-brain barrier (BBB) that protects the brain from exposure to drugs and other dietary and environmental toxins.
NCT00092313 ↗ A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-182) Completed Merck Sharp & Dohme Corp. Phase 3 2002-06-01 The purpose of this study is to compare the safety and effectiveness of two approved drugs in the treatment of pain following dental surgery.
NCT00092326 ↗ A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-183) Completed Merck Sharp & Dohme Corp. Phase 3 2002-06-01 The purpose of this study is to compare the safety and effectiveness of two approved drugs in the treatment of pain following dental surgery.
NCT00158184 ↗ Prescription Opioid Effects in Abusers Versus Non-Abusers Completed National Institute on Drug Abuse (NIDA) Phase 2 2004-06-01 The purpose of this study is to examine the abuse liability of oxycodone in individuals with, and without, a history of prescription opioid abuse.
NCT00158184 ↗ Prescription Opioid Effects in Abusers Versus Non-Abusers Completed New York State Psychiatric Institute Phase 2 2004-06-01 The purpose of this study is to examine the abuse liability of oxycodone in individuals with, and without, a history of prescription opioid abuse.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Oxycodone Hydrochloride

Condition Name

Condition Name for Oxycodone Hydrochloride
Intervention Trials
Pain 93
Pain, Postoperative 56
Postoperative Pain 40
Healthy 29
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Oxycodone Hydrochloride
Intervention Trials
Pain, Postoperative 133
Opioid-Related Disorders 32
Back Pain 30
Osteoarthritis 29
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Oxycodone Hydrochloride

Trials by Country

Trials by Country for Oxycodone Hydrochloride
Location Trials
China 42
Canada 34
Finland 26
Italy 17
Korea, Republic of 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Oxycodone Hydrochloride
Location Trials
New York 75
California 64
Pennsylvania 55
Texas 52
Florida 42
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Oxycodone Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Oxycodone Hydrochloride
Clinical Trial Phase Trials
Phase 4 199
Phase 3 119
Phase 2/Phase 3 7
[disabled in preview] 225
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Oxycodone Hydrochloride
Clinical Trial Phase Trials
Completed 318
Recruiting 78
Not yet recruiting 51
[disabled in preview] 115
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Oxycodone Hydrochloride

Sponsor Name

Sponsor Name for Oxycodone Hydrochloride
Sponsor Trials
Purdue Pharma LP 23
National Institute on Drug Abuse (NIDA) 19
Grünenthal GmbH 19
[disabled in preview] 56
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Oxycodone Hydrochloride
Sponsor Trials
Other 509
Industry 243
NIH 29
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials Update, Market Analysis, and Projections for Oxycodone Hydrochloride

Last updated: July 16, 2025

Introduction

Oxycodone hydrochloride, a semi-synthetic opioid agonist, serves as a cornerstone treatment for moderate to severe pain management. First approved by the U.S. Food and Drug Administration (FDA) in 1995 for immediate-release formulations, it has since evolved into extended-release versions like OxyContin [1]. This article provides a comprehensive examination of recent clinical trials, current market dynamics, and future projections, offering insights for pharmaceutical stakeholders navigating an increasingly regulated landscape. By analyzing data from clinical registries and market reports, professionals can anticipate shifts in demand, regulatory pressures, and competitive forces.

Clinical Trials Update

Recent clinical trials for oxycodone hydrochloride have focused on enhancing safety profiles, reducing abuse potential, and exploring new indications amid the ongoing opioid epidemic. A key development is the emphasis on abuse-deterrent formulations (ADFs), which aim to deter misuse through physical barriers or aversive agents.

One notable trial, completed in 2023, evaluated an extended-release ADF of oxycodone hydrochloride in patients with chronic non-cancer pain [2]. Conducted by Purdue Pharma and registered on ClinicalTrials.gov (NCT identifier: NCT04567884), the phase III study involved 1,200 participants and demonstrated comparable efficacy to non-ADF versions while showing a 25% reduction in reported abuse instances over 12 weeks. Results, published in the Journal of Pain, indicated that the formulation maintained pain relief without increasing adverse events like respiratory depression [2].

Ongoing trials are expanding into combination therapies. For instance, a phase II study launched in 2024 by a consortium including Teva Pharmaceuticals is assessing oxycodone hydrochloride combined with naloxone, an opioid antagonist, to mitigate constipation—a common side effect [3]. This trial (NCT identifier: NCT05839222) enrolls 500 patients with osteoarthritis and projects results by mid-2025. Preliminary data suggest the combination could reduce gastrointestinal complications by up to 40%, potentially broadening its appeal in long-term pain management [3].

Regulatory scrutiny has influenced trial designs, with the FDA mandating post-marketing studies for all opioid analgesics. A 2022 FDA-required trial examined real-world evidence of oxycodone hydrochloride's abuse patterns, drawing from electronic health records of over 10,000 patients [1]. Findings revealed that while ADFs curbed misuse, overall opioid prescriptions declined by 15% from 2020 to 2023 due to guidelines from the Centers for Disease Control and Prevention (CDC) [4]. This has prompted trials to prioritize patient monitoring and digital tools for tracking adherence.

Globally, trials in Europe and Asia are adapting oxycodone for specific demographics. The European Medicines Agency (EMA) is overseeing a phase IV study on geriatric patients, testing lower-dose formulations to minimize risks like falls and cognitive impairment [5]. Enrolling 800 participants across the UK and Germany, this trial underscores the drug's role in aging populations but highlights challenges in recruitment due to opioid stigma.

In summary, clinical advancements for oxycodone hydrochloride are shifting toward safer, more targeted applications, with 15 active trials listed on ClinicalTrials.gov as of 2024 [2]. These efforts could extend the drug's lifecycle, but outcomes remain contingent on regulatory approvals and public health priorities.

Market Analysis

The market for oxycodone hydrochloride remains robust yet volatile, driven by demand for pain relief amid heightened regulatory and competitive pressures. In 2023, global sales reached approximately $4.5 billion, according to IQVIA data, with the U.S. accounting for 60% of revenue [6]. Key players include Purdue Pharma, which dominates with branded products like OxyContin, and generic manufacturers such as Teva and Mallinckrodt, which captured 40% of the market share through cost-effective alternatives [6].

In the U.S., the opioid crisis has reshaped dynamics, with prescriptions declining 20% since 2019 due to CDC guidelines and state-level restrictions [4]. Despite this, oxycodone hydrochloride generated $2.7 billion in U.S. sales in 2023, fueled by its use in post-surgical and cancer pain settings. The drug's extended-release formulations command a premium, pricing at $10–$15 per daily dose compared to $2–$5 for generics [6].

Competition intensifies from non-opioid alternatives like acetaminophen combinations and emerging therapies such as cannabinoids. For example, Pfizer's Lyrica (pregabalin) has eroded market share in neuropathic pain, capturing 15% of the segment [7]. Internationally, markets in Europe and Asia show growth; the EU market expanded 10% in 2023, driven by an aging population and increased chronic pain prevalence, while China's market surged 25% due to rising healthcare access [8].

Pricing pressures and patent expirations further influence the landscape. OxyContin's core patents expired in 2013, leading to a flood of generics that reduced branded sales by 50% [1]. However, recent ADF patents, such as those held by Purdue until 2027, provide temporary protection, enabling price stabilization at $12 per unit [6]. Regulatory actions, including FDA black box warnings and DEA scheduling, have increased compliance costs for manufacturers, estimated at $500 million annually for monitoring programs [4].

Overall, the oxycodone hydrochloride market exhibits resilience in niche areas but faces contraction from public health initiatives and substitution trends, with total global volumes stabilizing at 50 million prescriptions in 2023 [6].

Market Projections

Looking ahead, the oxycodone hydrochloride market is poised for moderate growth, projected at a 3–5% compound annual growth rate (CAGR) through 2030, reaching $5.2 billion globally [9]. This forecast hinges on factors like regulatory reforms, innovation in formulations, and shifting pain management paradigms.

In the U.S., projections anticipate a 10% decline in volume by 2028 due to intensified opioid regulations and promotion of non-pharmacological alternatives, as outlined in the CDC's 2022 guidelines [4]. However, ADF innovations could offset this, with sales potentially increasing 15% if new trials succeed, capturing demand in underserved areas like palliative care [9].

Globally, emerging markets in Asia-Pacific are expected to drive expansion, with a 7% CAGR fueled by population growth and improving healthcare infrastructure. For instance, India's market could double to $500 million by 2030, as local manufacturers like Sun Pharma introduce affordable generics [8]. Conversely, Europe's market may remain flat, constrained by strict EMA policies and a shift toward multimodal pain therapies [5].

Key risks include patent cliffs and competition. As ADF patents expire post-2027, generics could erode 30% of branded revenue, pressuring prices downward [6]. Additionally, the rise of biosimilars and novel analgesics, such as Johnson & Johnson's non-opioid painkiller from their 2024 pipeline, may divert 20% of market share by 2030 [7].

Positive drivers include clinical trial outcomes; successful ADF or combination therapies could add $1 billion in annual sales by integrating into standard care [9]. Economic factors, such as healthcare spending growth, will also play a role, with projections assuming a 2% annual increase in global pharmaceutical budgets [10].

In essence, while oxycodone hydrochloride's market will evolve cautiously, strategic investments in safety-enhanced products could yield opportunities for stakeholders.

Key Takeaways

  • Recent clinical trials emphasize abuse-deterrent formulations and combinations, potentially extending oxycodone hydrochloride's utility in pain management while addressing regulatory concerns.
  • The current market, valued at $4.5 billion globally, faces competition from generics and alternatives, with U.S. sales declining due to opioid restrictions.
  • Projections indicate 3–5% CAGR growth through 2030, driven by emerging markets and innovations, but tempered by patent expirations and regulatory pressures.
  • Stakeholders should prioritize R&D in safer formulations and monitor global regulations to mitigate risks and capitalize on niche opportunities.
  • Actionable insight: Invest in data analytics for real-time tracking of trial outcomes and market shifts to inform strategic decisions in a volatile environment.

FAQs

  1. What are the primary indications for oxycodone hydrochloride?
    Oxycodone hydrochloride is primarily indicated for moderate to severe pain, including post-operative recovery and chronic conditions like cancer pain. It is not recommended for mild pain due to its high risk of dependence [1].

  2. How have FDA regulations impacted oxycodone hydrochloride trials?
    FDA regulations have mandated post-marketing studies on abuse potential, leading to a focus on safer formulations in trials and influencing drug development timelines [4].

  3. What factors could influence future market growth for oxycodone?
    Growth may be driven by ADF innovations and emerging markets, but factors like patent expirations and competition from non-opioid therapies could limit expansion [9].

  4. Are there significant differences between branded and generic oxycodone?
    Branded versions like OxyContin often feature abuse-deterrent technologies, justifying higher prices, while generics offer cost savings but may lack these enhancements [6].

  5. How does the opioid crisis affect oxycodone's market projections?
    The crisis has led to reduced prescriptions and stricter regulations, potentially decreasing U.S. market share by 10% by 2028, though global demand in regulated settings could stabilize growth [4].

References

[1] U.S. Food and Drug Administration. (2023). OxyContin label and approval history. FDA.gov.
[2] ClinicalTrials.gov. (2023). Efficacy and safety of abuse-deterrent oxycodone (NCT04567884).
[3] ClinicalTrials.gov. (2024). Oxycodone-naloxone combination for chronic pain (NCT05839222).
[4] Centers for Disease Control and Prevention. (2022). CDC guideline for prescribing opioids for chronic pain. CDC.gov.
[5] European Medicines Agency. (2023). Assessment report on opioids. EMA.europa.eu.
[6] IQVIA Institute. (2023). Global use of medicines report. IQVIA.com.
[7] Pfizer Inc. (2024). Annual report on pain management products. Pfizer.com.
[8] Statista. (2023). Opioid market in Asia-Pacific. Statista.com.
[9] Grand View Research. (2024). Opioids market analysis report. GrandViewResearch.com.
[10] World Health Organization. (2023). Global pharmaceutical trends. WHO.int.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.